Education Program
Leukemia, CLL, Diseases, Therapies, Adverse Events, B-Cell Lymphoma, Lymphoid Malignancies
Description:
The last 5-10 years have been an incredible time for patients with CLL given the advent of novel agents such as venetoclax, BTK and PI3K inhibitors. The use of these therapies has resulted in high response rates and long progression-free survival even in patients with high-risk, relapsed or refractory disease. As life-changing as these therapies have been in the care of CLL patients however, these agents have unique side effects which have required providers to gain familiarity and adapt their practice accordingly. This educational session will review the toxicity profiles of the most commonly used novel agents currently used to treat CLL patients, and will address the challenges and potential strategies to assess and manage real-world toxicity of these agents. Dr. Kirsten Fischer will summarize recent clinical advances with regards to preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax in therapy of CLL. She will discuss the opportunities and challenges associated with the treatment of venetoclax and will provide recommendations on how to optimize therapy with venetoclax. Dr. Lamanna will review the clinical data with regards to the incidence and management of toxicities related to Bruton’s tyrosine kinase (BTK) inhibitors with a focus on clinical implications and applicability. She will discuss next generation BTK inhibitors as well as potential combination strategies that are being evaluated. Dr. Danielle Brander will discuss the identification and management of the early and late onset toxicities that can arise with the use of phosphoinositide-3-kinase (PI3K) inhibitors for treatment of patients with CLL. This will include a review of clinical trials investigating next generation PI3K inhibitors, combination therapy, and/or dosing schedules that may mitigate toxicity risk.
Chair:
Nicole Lamanna, MD, Columbia University Medical Center
Disclosures:
Lamanna: Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bei-Gene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Juno: Other: Institutional research grants, Research Funding; MingSight: Other: Institutional research grants, Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncternal, Verastem, TG Therapeutics: Other: Institutional research grants, Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Astra Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Loxo: Research Funding; Octapharma: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional research grants, Research Funding; Columbia University Medical Center: Current Employment.
The last 5-10 years have been an incredible time for patients with CLL given the advent of novel agents such as venetoclax, BTK and PI3K inhibitors. The use of these therapies has resulted in high response rates and long progression-free survival even in patients with high-risk, relapsed or refractory disease. As life-changing as these therapies have been in the care of CLL patients however, these agents have unique side effects which have required providers to gain familiarity and adapt their practice accordingly. This educational session will review the toxicity profiles of the most commonly used novel agents currently used to treat CLL patients, and will address the challenges and potential strategies to assess and manage real-world toxicity of these agents. Dr. Kirsten Fischer will summarize recent clinical advances with regards to preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax in therapy of CLL. She will discuss the opportunities and challenges associated with the treatment of venetoclax and will provide recommendations on how to optimize therapy with venetoclax. Dr. Lamanna will review the clinical data with regards to the incidence and management of toxicities related to Bruton’s tyrosine kinase (BTK) inhibitors with a focus on clinical implications and applicability. She will discuss next generation BTK inhibitors as well as potential combination strategies that are being evaluated. Dr. Danielle Brander will discuss the identification and management of the early and late onset toxicities that can arise with the use of phosphoinositide-3-kinase (PI3K) inhibitors for treatment of patients with CLL. This will include a review of clinical trials investigating next generation PI3K inhibitors, combination therapy, and/or dosing schedules that may mitigate toxicity risk.
Kirsten Fischer, MD
University Hospital Cologne, Cologne, Germany
Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
Danielle M. Brander, MD
Duke Cancer Institute, Duke University, Durham, NC
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.